Ireland· IE-PA-EU/1/21/1558/001
Klisyri 10 mg/g ointment
A tirbanibulin product containing tirbanibulin, registered in Ireland by Almirall, S.A.. The same ATC class is registered in 12 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Tirbanibulin is registered in 12 of 19 countries.
Countries holding a registration under ATC D06BX03 (tirbanibulin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Tirbanibulin · ATC D06BX03
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Tirbanibulin
- Manufacturer
- Almirall, S.A.
- Country
- Ireland (IE)
- ATC code
- D06BX03
- ATC class
- Tirbanibulin
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/21/1558/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tirbanibulin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKlisyri 10 mg/gAlmirall
- United KingdomKlisyri 10mg/g ointment 250mg sachetsAlmirall Ltd
- United StatesKlisyriAlmirall, LLC
- CzechiaKLISYRIAlmirall, S.A., Barcelona
- SpainKLISYRI 10 MG/G POMADAAlmirall S.A.
- FinlandKlisyriAlmirall S.A.
- ItalyKLISYRI*unguento cutaneo 5 buste 250 g 10 mg/gALMIRALL S.A.
- NetherlandsKlisyri 10 mg/g, zalfGrupo Farmacéutico Almirall S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Klisyri
- Liechtenstein · Klisyri
- Norway · Klisyri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5da29a7-4ece-4627-842e-9ebf41041e38 GET /v1/drugs/c5da29a7-4ece-4627-842e-9ebf41041e38?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Ointment",
"routes": null,
"source": "hpra",
"atc_all": [
"D06BX03"
],
"strength": null,
"pa_number": "EU/1/21/1558/001",
"substances": [
"Tirbanibulin"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "16/07/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about tirbanibulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.